{"id":335948,"date":"2019-07-22T09:28:07","date_gmt":"2019-07-22T07:28:07","guid":{"rendered":"https:\/\/medizinonline.com\/un-diagnostic-differencie-pour-des-resultats-efficaces\/"},"modified":"2019-07-22T09:28:07","modified_gmt":"2019-07-22T07:28:07","slug":"un-diagnostic-differencie-pour-des-resultats-efficaces","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/un-diagnostic-differencie-pour-des-resultats-efficaces\/","title":{"rendered":"Un diagnostic diff\u00e9renci\u00e9 pour des r\u00e9sultats efficaces"},"content":{"rendered":"<p><strong>Des possibilit\u00e9s de diagnostic diff\u00e9renci\u00e9es doivent permettre une th\u00e9rapie individuelle et adapt\u00e9e aux besoins de chacun. Cependant, dans le cas des n\u00e9oplasies h\u00e9matologiques, les options de traitement \u00e9tablies sont \u00e9galement efficaces.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>Pour le traitement du lymphome indolent rare, on utilise principalement le R-Benda (rituximab et bendamustine), le DRC (dexam\u00e9thasone, rituximab et cyclophosphamide) et le BDR (bort\u00e9zomib, dexam\u00e9thasone et rituximab). Ces trois r\u00e9gimes ont \u00e9t\u00e9 compar\u00e9s en termes d&#8217;efficacit\u00e9. Ont \u00e9t\u00e9 inclus les patients atteints de MW qui ont \u00e9t\u00e9 examin\u00e9s \u00e0 la Mayo Clinic entre 2000 et 2018 et qui ont \u00e9t\u00e9 mis sous l&#8217;un des trois traitements de premi\u00e8re ligne.<\/p>\n<p>Un net avantage a \u00e9t\u00e9 constat\u00e9 pour la combinaison de rituximab et de bendamustine (R-Benda). L&#8217;ORR \u00e9tait de 95%, alors que le BDR \u00e9tait de 81% et le DRC de 76%. Des r\u00e9missions compl\u00e8tes de tout de m\u00eame 10% ont \u00e9t\u00e9 d\u00e9montr\u00e9es uniquement pour le r\u00e9gime R-Benda. Une tr\u00e8s bonne r\u00e9mission partielle (VGPR) \u00e9tait de 21% et une r\u00e9mission partielle de 62% <strong>(Fig.&nbsp;1).<\/strong> En revanche, il n&#8217;y a pas eu de diff\u00e9rence entre les diff\u00e9rentes approches th\u00e9rapeutiques en termes de survie globale.<\/p>\n<p>La cohorte r\u00e9trospective a d\u00e9montr\u00e9 qu&#8217;un traitement de premi\u00e8re ligne par R-Benda \u00e9tait sup\u00e9rieur \u00e0 la DRC ou \u00e0 la BDR en termes de r\u00e9ponse, de d\u00e9lai avant le traitement suivant et de survie sans progression, ind\u00e9pendamment de la pr\u00e9sence d&#8217;une mutation MYD88L265P. En ce qui concerne leur profil de toxicit\u00e9, les trois r\u00e9gimes \u00e9taient comparables. Seuls les BDR ont entra\u00een\u00e9 une neurotoxicit\u00e9 de grade 3 dans 13% des cas.<\/p>\n<p>&nbsp;<\/p>\n<p>\nLitt\u00e9rature compl\u00e9mentaire :<\/p>\n<ul>\n<li>Abeykoon JP, et al. : Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, caclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). ASCO Annual Meeting 2019, Abstract 7509.<\/li>\n<\/ul>\n<p>\n<em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2019 ;(2-3) : 30 (publi\u00e9 le 17.6.19, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Des possibilit\u00e9s de diagnostic diff\u00e9renci\u00e9es doivent permettre une th\u00e9rapie individuelle et adapt\u00e9e aux besoins de chacun. Cependant, dans le cas des n\u00e9oplasies h\u00e9matologiques, les options de traitement \u00e9tablies sont \u00e9galement&hellip;<\/p>\n","protected":false},"author":7,"featured_media":90142,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"N\u00e9oplasies h\u00e9matologiques","footnotes":""},"category":[11527,11373,11389,11535,11549],"tags":[28347,28341,19432],"powerkit_post_featured":[],"class_list":["post-335948","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-hematologie","category-oncologie","category-rapports-de-congres","category-rx-fr","tag-macroglobulinemie-de-waldenstroem","tag-neoplasies-hematologiques","tag-traitement-de-premiere-ligne","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-13 05:02:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":335956,"slug":"diagnostica-differenziata-per-risultati-efficaci","post_title":"Diagnostica differenziata per risultati efficaci","href":"https:\/\/medizinonline.com\/it\/diagnostica-differenziata-per-risultati-efficaci\/"},"pt_PT":{"locale":"pt_PT","id":335963,"slug":"diagnosticos-diferenciados-para-resultados-eficazes","post_title":"Diagn\u00f3sticos diferenciados para resultados eficazes","href":"https:\/\/medizinonline.com\/pt-pt\/diagnosticos-diferenciados-para-resultados-eficazes\/"},"es_ES":{"locale":"es_ES","id":335928,"slug":"diagnosticos-diferenciados-para-resultados-eficaces","post_title":"Diagn\u00f3sticos diferenciados para resultados eficaces","href":"https:\/\/medizinonline.com\/es\/diagnosticos-diferenciados-para-resultados-eficaces\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=335948"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335948\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=335948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=335948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=335948"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=335948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}